AI Science Tracker

Prospective multicentre study combines EV protein biomarkers and machine learning for preclinical oesophageal cancer detection

Sun Yat-sen University Cancer Center; and collaborating hospitals/cohorts · 3 Mar 2026 · medicine

Discovery

Prospective multicentre study combines EV protein biomarkers and machine learning for preclinical oesophageal cancer detection

The BarFlare assay and an interpretable multi-criteria decision-making classification-fusion machine-learning framework combined extracellular-vesicle SCC and MMP13 biomarkers with clinical factors. The model was evaluated in prospective multicentre diagnostic cohorts and two population cohorts; the longitudinal cohort contained baseline samples from 30 people who later developed oesophageal squamous cell carcinoma, with a reported median lead time of 34.9 months and AUC 0.864. The paper also reports external diagnostic validation in two cohorts.

Technology: Multi-criteria decision-making Classification Fusion (MCF) machine-learning framework; 289 candidate feature-selector/classifier pairs were compared and three base models fused

Publication: Peer-reviewed paper · Test context: prospective or independent check. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: prospective or independent check
  • Tested: The BarFlare assay and an interpretable multi-criteria decision-making classification-fusion machine-learning framework combined extracellular-vesicle SCC and MMP13 biomarkers with clinical factors.
  • Still unknown: This is a prospective observational diagnostic study, not an intervention trial or proof that screening improves outcomes. The longitudinal preclinical cohort had 30 incident cases and matched controls; performance estimates require external replication in larger populations. The source reports an association and lead time, not guaranteed individual prediction. Primary publisher full text and abstract checked; no independent replication assessed.
  • AI role: The MCF framework integrated newly identified EV biomarkers with clinical variables, selected and fused machine-learning classifiers, and produced the risk score evaluated in diagnostic and prospective population cohorts. BarFlare is the high-sensitivity EV assay platform, not the AI model.

Evidence sources: https://isevjournals.onlinelibrary.wiley.com/doi/10.1002/jev2.70246

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 4/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.